Commercialization Intelligence StudioExecutive Commercialization Decision Environment
Commercialization Intelligence Studio
Commercialization decision intelligence for pharma growth, market access, and launch strategy.
Step 06 · Stakeholder Intelligence

Boardroom Commercialization Intelligence

Commercialization outcomes depend on stakeholder alignment. Role-based inputs are synthesized into a prioritized commercialization recommendation informed by business risk, launch signals, and execution realities.

Role-based intelligenceExecutive synthesisEvidence-informed decisioningBriefed on · Ultra-Rare Neurology Therapy
Key Question

Where should we concentrate the first 90 days of commercialization investment to compress time-to-therapy?

Executive commercialization question for the first 90 days of launch.

Ultra-rare neurology launch · 47-day median time-to-therapy · 29% abandonment · payer coverage 61% · concentrated prescribers across 38 reference centers.

Stakeholder Lean
Coverage3/7 · 43%
Adoption2/7 · 29%
Evidence1/7 · 14%
Workflow1/7 · 14%
Stakeholder Misalignment Detected

Competing commercialization priorities may constrain execution unless sequencing is aligned.

Stakeholder Inputs

Structured inputs from the commercial leadership table.

SVP Market Access
Owns payer strategy & coverage architecture
Optimize · Coverage
Recommendation
Prioritize payer readiness ahead of broad activation.
Key Rationale
Coverage friction risk is high; PA denial rate at 42% will throttle every downstream lever.
Signal
Coverage 61% · PA denial 42%
HEOR Director
Owns evidence & value narrative
Optimize · Evidence
Recommendation
Comparative effectiveness evidence package first.
Key Rationale
Stronger payer leverage; supports preferred status across regional plans.
Signal
RWE gap pre-launch
Director, Field Reimbursement
Owns FRM operations & HUB execution
Optimize · Workflow
Recommendation
Increase reimbursement support and AI-triaged HUB workflow.
Key Rationale
Time-to-therapy delays expected at PA + benefits verification; abandonment compounds daily.
Signal
29% abandonment · 47d TTT
SVP Sales
Owns field deployment & account strategy
Optimize · Adoption
Recommendation
Centers of excellence targeting in 12 priority geos.
Key Rationale
High prescribing concentration — top 38 centers cover ~71% of diagnosed patients.
Signal
71% concentration · 38 centers
SVP Marketing
Owns brand & disease-state narrative
Optimize · Adoption
Recommendation
Disease-state education paired with patient finder model.
Key Rationale
Diagnosis lag is the upstream constraint; brand pull only matters once patients are identified.
Signal
<2,400 eligible patients
Director, Market Access
Owns regional payer execution
Optimize · Coverage
Recommendation
Regional payer narrative kits aligned to top 14 plans.
Key Rationale
Narrative inconsistency across regions is eroding pull-through.
Signal
Regional variance ±18%
CEO / CCO
Owns enterprise commercial outcome
Optimize · Coverage
Recommendation
De-risk launch predictability before scaling reach.
Key Rationale
Investor narrative depends on early access proof points; abandonment is the most visible failure mode.
Signal
$182M revenue-at-risk
Executive Insight
Alignment is the launch lever.

Commercialization failure often stems from organizational misalignment rather than strategy quality. Stakeholder synthesis enables leadership to sequence interventions before friction compounds.

Executive Synthesis

Stakeholder inputs, synthesized into a recommended commercial decision.

Synthesis weighs role-based recommendations, confidence, and signal strength — surfacing alignment, tension, and the recommended pathway forward.

Alignment
  • Coverage is the binding constraint
  • HUB workflow must move first
Tension
  • Sales prefers earlier broad activation
  • Marketing wants disease-state lead
Recommended Decision
Confidence
High

Anchor first 90 days on payer & access readiness; activate reference centers in parallel.

Recommended Pathway
Coverage-first pathway with AI-triaged HUB and CoE activation as a paired motion.
Expected Business Impact
Compress time-to-therapy 47 → 22 days · recapture ~$48M of revenue-at-risk · stabilize launch trajectory.
Sequencing
  1. 01Weeks 0–4 · Payer narrative kits + regional alignment
  2. 02Weeks 2–8 · AI-triaged HUB workflow live in priority geos
  3. 03Weeks 6–12 · CoE activation across 38 reference centers
Explore Alignment Scenarios→See How CIS Works→
←Analogs
Activation→